Cash Flow Statement

Amortizatization of Intangibles Amortizatization of Intangibles Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Change in Intangibles Change in Intangibles Change in Inventory Change in Inventory Change in Receivables Change in Receivables Deferred Taxes Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Exchange Rate Effect Exchange Rate Effect Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Long-Term Debt Repayments Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other Working Capital Changes Other Working Capital Changes Sales of Property, Plant and Equipment Sales of Property, Plant and Equipment Share-based Compensation Share-based Compensation Shares Issued

Daily Values

Growth Metrics

Others

Acadia Pharmaceuticals (ACAD) Change in Intangibles (2025)

Acadia Pharmaceuticals has reported Change in Intangibles over the past 1 years, most recently at $98.8 million for Q1 2025.

For Q1 2025, Change in Intangibles changed N/A year-over-year to $98.8 million; the TTM value through Dec 2025 reached $98.8 million, changed N/A, while the annual FY2025 figure was $98.8 million, N/A changed from the prior year.
Change in Intangibles for Q1 2025 was $98.8 million at Acadia Pharmaceuticals.
Over five years, Change in Intangibles peaked at $98.8 million in Q1 2025 and troughed at $98.8 million in Q1 2025.